Eisai announced today that 12 abstracts highlighting new study results will be presented during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, USA, from 1-5 June 2012.
These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's commitment to patients and their families affected by cancer.
"Our human health care mission is to help address unmet medical needs and increase benefits to patients and their families," said Takashi Owa, Ph.D., Chief Scientific Officer, Eisai Product Creation Systems. "Our portfolio of oncology compounds and therapies underscores our commitment to this important mission."
The following Eisai abstracts are accepted for presentation at this year's ASCO meeting:
Product Abstract Name
A Phase II Single Arm, Feasibility Study of Dose Dense
Doxorubicin and Cyclophosphamide (AC) Followed by
Eribulin Eribulin Mesylate for the Adjuvant Treatment of Early
Stage Breast Cancer (EBC)
Abstract No:
TPS1145 Poster Session
A Phase 1b Dose Escalation Study of Eribulin Mesylate in
Combination with Capecitabine in Patients with
Eribulin Advanced/Metastatic Cancer
Abstract No: 2552 Poster Session
Lenvatinib
(E7080) Treatment of Refractory Metastatic Renal Cell Carcinoma
(RCC) with Lenvatinib (E7080) and Everolimus
Abstract No:
TPS4682 Poster Session
Lenvatinib
A Phase IB Study of Lenvatinib (E7080) in Combination
(E7080) with Temozolomide for Treatment of Advanced Melanoma
Abstract No: 8594 Poster Session
Lenvatinib Treatment of Advanced RAI-refractory
Differentiated Thyroid Cancer (DTC); Cytokine and
Lenvatinib Angiongenic Factor (CAF) Profiling in Combination with
Tumour Genetic Analysis to Identify Markers Associated
E7080 with Response
Abstract No: 5518 Poster Discussion
Lenvatinib A Phase II Trial of the Multitargeted Kinase Inhibitor
Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
(E7080) (MTC)
Abstract No: 5591 Poster Session
A Phase I Dose-Finding Study of of Golvatinib (E7050) a
cMET and Eph Receptor Targeted Multi-Kinase Inhibitor,
Administered Orally QD to Patients with Advanced Solid
E7050 Tumours
Abstract No: 3030 Poster Discussion
A Phase I Dose-Finding Study of Golvatinib (E7050), a
c-Met and EPH Receptor Targeted Multi-Kinase Inhibitor
Administered Orally BID to Patients with Advanced Solid
E7050 Tumours
Abstract No: 3079 Poster Session
Phase I Safety Study of Farletuzumab, Carboplatin and
Pegylated Liposomal Doxorubicin (PLD) in Patients with
Farletuzumab Platinum-Sensitive Epithelial Ovarian Cancer (EOC)
MORAb-003
Abstract No: 5062 Poster Session
Phase I and Pharmacokinetic Study of Farletuzumab in
Farletuzumab Solid Tumours
MORAb-003
Abstract No: 3084 Poster Session
Amatuximab, A Chimeric Monoclonal Antibody to
Amatuximab Mesothelin, in Combination with Pemetrexed and Cisplatin
in Patients with Unresectable Pleural Mesothelioma
MORAb-009 Results of a Multicentre Phase II Clinical Trial
Abstract No: 7030 Poster Discussion
A First-in-Human Phase I Study of MORAb-004 (M4), a
Humanised Monoclonal Antibody Recognising Endosialin
MORAb-004 (TEM-1), in Patients with Solid Tumours
Abstract No: 3016 Poster Discussion
No comments:
Post a Comment